RxDoctor Payments Data

Hasan Imanli, MD

Internal Medicine · Baltimore, MDNPI 1205325628

Payments from drug & device makers

$257in general payments, 2019–2025

Across 7 payments — averaging $36.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urovant Sciences Inc$125
  • Bayer$50
  • Teva Pharmaceuticals USA, Inc.$26
  • Novo Nordisk$25
  • Avanir Pharmaceuticals, Inc.$17
  • Otsuka America Pharmaceutical, Inc.$15

What the payments were for

  • Food & beverage$24394%
  • Education$156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$257 in reported general payments places this provider in the 55th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$379,329
Medicare patients
318
Services billed
4,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban749$191,452
Humira(Cf) PenAdalimumab24$176,461
JardianceEmpagliflozin334$104,659
TrulicityDulaglutide145$72,175
OzempicSemaglutide63$65,726
TriumeqAbacavir/Dolutegravir/Lamivudi12$48,136
FarxigaDapagliflozin Propanediol134$44,163
SantylCollagenase Clostridium Hist.14$33,381
EntrestoSacubitril/Valsartan124$31,633
ProcritEpoetin Alfa13$30,758
XareltoRivaroxaban118$29,313
JanuviaSitagliptin Phosphate105$25,726
LokelmaSodium Zirconium Cyclosilicate66$23,008
Risperdal ConstaRisperidone Microspheres29$17,536
AbrysvoRsv Vacc, Pref A And Pref B/Pf47$14,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$25$78,18375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →